Related Experiment Video

Updated: Jun 11, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

HFE gene polymorphisms and severity in Portuguese patients with multiple sclerosis

A Bettencourt1, A M Silva, E Santos

  • 1UMIB - Instituto de Ciências Biomédicas Abel Salazar (ICBAS-UP), Porto, Portugal. ambettencourt@icbas.up.pt

European Journal of Neurology
|July 1, 2010
PubMed
Abstract

Insights

The HFE gene C282Y variant may indicate a worse prognosis in multiple sclerosis (MS) patients, though it does not affect disease susceptibility. This finding is crucial for understanding MS progression and patient outcomes.

Area of Science:

  • Neuroimmunology
  • Genetics
  • Iron Metabolism

Background:

  • Elevated iron levels are observed in multiple sclerosis (MS) lesions within oligodendrocytes, myelin, and macrophages.
  • HFE gene polymorphisms are hypothesized to influence MS development and progression.

Purpose of the Study:

  • To investigate the association between HFE gene polymorphisms (C282Y and H63D) and multiple sclerosis (MS).
  • To determine if HFE variants impact MS susceptibility and disease severity.

Main Methods:

  • Genotyping for C282Y and H63D HFE variants was performed in 373 MS patients.
  • Allele and genotype frequencies were compared between MS patients and a control population.
  • Association analysis was conducted between HFE genotypes and MS disease severity.

Main Results:

  • No significant link was found between HFE polymorphisms and the susceptibility to developing MS.
  • The C282Y HFE allele was observed more frequently in patients with aggressive MS.
  • HFE genotype analysis suggested a correlation with disease severity.

Conclusions:

  • The C282Y HFE variant appears to be associated with a poorer prognosis in multiple sclerosis patients.
  • This suggests a potential role for specific HFE genotypes in modulating MS disease course.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...